Esperion Therapeutics | ESPR - Net Income


Esperion Therapeutics reported $61.83M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cipla INR 5.55B 1.21B Mar/2026
CSL USD 401M 96.5M Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Geron USD -3.64M 27.5M Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024